Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
Identifieur interne : 003086 ( PubMed/Curation ); précédent : 003085; suivant : 003087Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
Auteurs : Carlos Singer [États-Unis] ; Spiridon Papapetropoulos ; Manuel A. Gonzalez ; Eugene L. Roberts ; Abraham LiebermanSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Aged, Amantadine (adverse effects), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Edema (drug therapy), Edema (etiology), Female, Humans, Middle Aged, Motor Activity (drug effects), Parkinson Disease (drug therapy), Rimantadine (therapeutic use), Severity of Illness Index.
- MESH :
- chemical , adverse effects : Amantadine, Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents, Rimantadine.
- drug effects : Motor Activity.
- drug therapy : Edema, Parkinson Disease.
- etiology : Edema.
- Aged, Female, Humans, Middle Aged, Severity of Illness Index.
Abstract
We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the alpha-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 +/- 5.9 years, the mean disease duration was 13 +/- 6.3 years, and mean Hoehn and Yahr stage was 2.2 +/- 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.
DOI: 10.1002/mds.20471
PubMed: 15809995
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003086
Links to Exploration step
pubmed:15809995Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.</title><author><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology University of Miami, School of Medicine, Miami, Florida 33136, USA. csinger@med.miami.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology University of Miami, School of Medicine, Miami, Florida 33136</wicri:regionArea></affiliation></author><author><name sortKey="Papapetropoulos, Spiridon" sort="Papapetropoulos, Spiridon" uniqKey="Papapetropoulos S" first="Spiridon" last="Papapetropoulos">Spiridon Papapetropoulos</name></author><author><name sortKey="Gonzalez, Manuel A" sort="Gonzalez, Manuel A" uniqKey="Gonzalez M" first="Manuel A" last="Gonzalez">Manuel A. Gonzalez</name></author><author><name sortKey="Roberts, Eugene L" sort="Roberts, Eugene L" uniqKey="Roberts E" first="Eugene L" last="Roberts">Eugene L. Roberts</name></author><author><name sortKey="Lieberman, Abraham" sort="Lieberman, Abraham" uniqKey="Lieberman A" first="Abraham" last="Lieberman">Abraham Lieberman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20471</idno><idno type="RBID">pubmed:15809995</idno><idno type="pmid">15809995</idno><idno type="wicri:Area/PubMed/Corpus">003086</idno><idno type="wicri:Area/PubMed/Curation">003086</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.</title><author><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology University of Miami, School of Medicine, Miami, Florida 33136, USA. csinger@med.miami.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology University of Miami, School of Medicine, Miami, Florida 33136</wicri:regionArea></affiliation></author><author><name sortKey="Papapetropoulos, Spiridon" sort="Papapetropoulos, Spiridon" uniqKey="Papapetropoulos S" first="Spiridon" last="Papapetropoulos">Spiridon Papapetropoulos</name></author><author><name sortKey="Gonzalez, Manuel A" sort="Gonzalez, Manuel A" uniqKey="Gonzalez M" first="Manuel A" last="Gonzalez">Manuel A. Gonzalez</name></author><author><name sortKey="Roberts, Eugene L" sort="Roberts, Eugene L" uniqKey="Roberts E" first="Eugene L" last="Roberts">Eugene L. Roberts</name></author><author><name sortKey="Lieberman, Abraham" sort="Lieberman, Abraham" uniqKey="Lieberman A" first="Abraham" last="Lieberman">Abraham Lieberman</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Amantadine (adverse effects)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Edema (drug therapy)</term><term>Edema (etiology)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Motor Activity (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Rimantadine (therapeutic use)</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Rimantadine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Edema</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Edema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the alpha-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 +/- 5.9 years, the mean disease duration was 13 +/- 6.3 years, and mean Hoehn and Yahr stage was 2.2 +/- 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15809995</PMID><DateCreated><Year>2005</Year><Month>07</Month><Day>13</Day></DateCreated><DateCompleted><Year>2005</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>7</Issue><PubDate><Year>2005</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.</ArticleTitle><Pagination><MedlinePgn>873-7</MedlinePgn></Pagination><Abstract><AbstractText>We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the alpha-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 +/- 5.9 years, the mean disease duration was 13 +/- 6.3 years, and mean Hoehn and Yahr stage was 2.2 +/- 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.</AbstractText><CopyrightInformation>Copyright 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology University of Miami, School of Medicine, Miami, Florida 33136, USA. csinger@med.miami.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papapetropoulos</LastName><ForeName>Spiridon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Manuel A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Eugene L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Abraham</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0T2EF4JQTU</RegistryNumber><NameOfSubstance UI="D012299">Rimantadine</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000547">Amantadine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004487">Edema</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012299">Rimantadine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20471</ArticleId><ArticleId IdType="pubmed">15809995</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003086 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003086 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15809995
|texte= Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15809995" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |